FUSE MEDICAL, INC. (OTCMKTS:FZMD) Files An 8-K Entry into a Material Definitive Agreement

0

FUSE MEDICAL, INC. (OTCMKTS:FZMD) Files An 8-K Entry into a Material Definitive Agreement
Item 9.01Entry Into a Material Definitive Agreement

On July 19, 2017, Fuse Medical, Inc. (the “Company”) entered into that certain Commercial Property Lease Agreement, dated to be effective July 14, 2017 (the “Lease”), by and between the Company and 1565 North Central Expressway, LP—an entity controlled by the Company’s largest stockholder, Mark W. Brooks. The Lease provides that the Company will pay rent of $4,000 per month and the initial term of the Lease begins on July 14, 2017 and ends December 31, 2017.A copy of the Lease is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 9.01

Termination of a Material Definitive Agreement

On July 17, 2017, the Company entered into that certain Assignment of Sublease and Consent, dated July 17, 2017 (the “Assignment Agreement”), by and between (i) PBIII-SOP, LP, (ii) PHILLIP GALYEN, PC, d/b/a Bailey & Galyen (“Galyen”), (iii) the Company, and (iv) LawConnect, Inc. d/b/a GetLegal.com (“LawConnect”). to the Assignment Agreement, the Company assigned to LawConnect all of the Company’s right, title, and interest in that certain Sublease Agreement, dated September 1, 2015 (the “Assigned Sublease”), by and between the Company and Galyen.The Assignment Agreement terminated all Obligations of the Company under the Assigned Sublease. A copy of the Assignment Agreement and the Assigned Sublease are filed as Exhibit 10.2 and Exhibit 10.3 to this Current Report on Form 8-K, respectively.

Item 9.01.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 13, 2017, the Board of Directors (the “Board”) of the Company appointed “Ricky” Raj S. Kalra, M.D. to serve as a member of the Board.

Dr. Kalra is a spine fellowship-trained neurosurgeon in Dallas, Texas. He attended Rice University where he received a degree in economics. He also attended London School of Economics as a Hansard Scholar. Dr. Kalra worked at Merrill Lynch in their investment banking sector after his undergraduate education. He then attended Washington University School of Medicine in Saint Louis and completed his neurosurgery residency at the University of Utah. As part of his spine fellowship, Dr. Kalra trained in Germany under Dr. Rudolf Beisse.Dr. Kalra has published more than twenty scientific articles and book chapters and has received the Preuss award by the Congress of Neurological Surgeons for his research in brain tumors.Dr. Kalra was appointed to the Board for his financial acumen as well as experience in the industry.

The Company and Dr. Kalra are parties to an Independent Contractor Agreement, dated July 1, 2017, whereby the Company agreed to pay Dr. Kalra $10,000 (the “Consulting Fee”) in return for the provision of his analysis and advice on certain strategic matters.The entire Consulting Fee was paid to Dr. Kalra prior to his appointment to the Board.

Item 9.01.

Financial Statements and Exhibits.

Exhibit

No.

Description

10.1

Commercial Property Lease Agreement dated July 19, 2017 by and between Fuse Medical, Inc. and 1565 North Central Expressway, LP.

10.2

Assignment of Sublease and Consent, dated July 17, 2017, by and between (i) PBIII-SOP, LP, (ii) PHILLIP GALYEN, PC, d/b/a Bailey & Galyen, (iii) Fuse Medical, Inc., and (iv) LawConnect, Inc. d/b/a GetLegal.com.

10.3

Sublease Agreement dated September 1, 2015, by and between Fuse Medical, Inc. and PHILLIP GALYEN, PC, d/b/a Bailey & Galyen.


Fuse Medical, Inc. Exhibit
EX-10.1 2 fzmd-ex101_44.htm EX-10.1 fzmd-ex101_44.htm EX – 10.1 Commercial Property Lease Agreement This Commercial Property Lease Agreement (“Lease”) is made and effective July 14,…
To view the full exhibit click here

About FUSE MEDICAL, INC. (OTCMKTS:FZMD)

Fuse Medical, Inc., formerly Golf Rounds.com, Inc., is engaged in marketing, distributing and selling internal fixation, bone materials, biologics, tissues, surgical and other related surgical products. The Company operates through medical products and supplies segment. The Company’s products consist of plates and screws for recurring bone fractures, allografts for bone chips and tendons, and amniotics. Its products are used in a range of surgical procedures in various types of facilities (ambulatory surgical centers, hospitals and physician offices, and other medical facilities) where surgeons and doctors treat patients and operate. It markets, distributes and sells a range of existing Food and Drug Administration-approved and state licensed products and services manufactured or produced by other organizations where it is considered as a distributor and a stocking distributor. Its customers are physicians, orthopedic surgeons, hospitals, surgical facilities and physician practices.